Juneflecad

Flecainide acetate, the active ingredient in Juneflecad, is a Class Ic antiarrhythmic presented as an oral formulation for oral use. It is employed to manage serious ventricular and supraventricular cardiac arrhythmias in adult patients.

GNH USA supplies Juneflecad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Juneflecad is indicated for cardiac rhythm disorders where rapid electrical conduction contributes to arrhythmia.

Ventricular arrhythmias: restores normal ventricular rhythm and reduces life‑threatening tachycardia episodes. Supraventricular arrhythmias (e.g., atrial fibrillation): decreases the frequency of irregular atrial beats and helps maintain sinus rhythm. Paroxysmal supraventricular tachycardia: terminates episodes by slowing atrioventricular conduction.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Visual disturbances: blurred vision or altered color perception. - Headache: mild to moderate pain in the head region. - Nausea: feeling of queasiness often accompanied by an urge to vomit.

Serious or Rare Side Effects: - Proarrhythmia: new or worsening arrhythmias, including ventricular tachycardia. - Severe bradycardia: markedly slowed heart rate that may cause hypotension. - Atrioventricular block: impaired conduction between atria and ventricles. - Sudden cardiac death: unexpected fatal cardiac event, particularly in patients with structural heart disease.

Before initiating therapy, clinicians should evaluate cardiac status and monitor for adverse reactions. - ECG monitoring: perform baseline and periodic electrocardiograms to detect conduction changes. - Renal/hepatic function: assess organ function as impairment may alter drug clearance. - Structural heart disease: avoid use in patients with prior myocardial infarction or significant cardiomyopathy. - Concomitant CYP2D6 inhibitors: adjust therapy if strong inhibitors are co‑administered. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Flecainide may interact with several cardiovascular and metabolic agents.

Major Interactions (Avoid): - Other Class I antiarrhythmics (e.g., quinidine, propafenone): additive sodium‑channel blockade can precipitate severe conduction delay. - Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): increase flecainide plasma concentrations and risk of toxicity. - Drugs that markedly prolong QRS duration (e.g., amiodarone): synergistic effect on ventricular conduction.

Moderate Interactions (Monitor Closely): - Beta‑blockers (e.g., metoprolol): may enhance bradycardic effects; monitor heart rate. - Calcium‑channel blockers (e.g., verapamil): can increase plasma levels; adjust dosage if needed. - Diuretics causing electrolyte shifts (e.g., furosemide): monitor potassium and magnesium to prevent proarrhythmic risk.